Charming Medical Limited (MCTA)

Charming Medical Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Revenue	6.22	6.02	3.53
Revenue Growth (YoY)	3.43%	70.37%	-
Cost of Revenue	0.2	0.17	0.05
Gross Profit	6.02	5.84	3.48
Selling, General & Admin	4.16	4.28	3.65
Operating Expenses	4.42	4.67	3.86
Operating Income	1.6	1.17	-0.38
Interest Expense	-0.02	-0.03	-0.02
Interest & Investment Income	0.06	0.02	0.01
Other Non Operating Income (Expenses)	-0.21	-0.16	-0.03
EBT Excluding Unusual Items	1.43	1	-0.42
Gain (Loss) on Sale of Investments	0	-	-
Pretax Income	1.44	1	-0.42
Income Tax Expense	0.24	0.18	-0.08
Earnings From Continuing Operations	1.2	0.82	-0.34
Minority Interest in Earnings	-	-0.04	0.03
Net Income	1.2	0.78	-0.31
Net Income to Common	1.2	0.78	-0.31
Net Income Growth	54.16%	-	-
Shares Outstanding (Basic)	15	15	15
Shares Outstanding (Diluted)	15	15	15
EPS (Basic)	0.08	0.05	-0.02
EPS (Diluted)	0.08	0.05	-0.02
EPS Growth	54.16%	-	-
Free Cash Flow	0.14	0.08	1.83
Free Cash Flow Per Share	0.01	0.01	0.12
Gross Margin	96.76%	97.17%	98.66%
Operating Margin	25.71%	19.49%	-10.73%
Profit Margin	19.27%	12.93%	-8.64%
Free Cash Flow Margin	2.22%	1.41%	51.76%
EBITDA	1.86	1.56	-0.17
EBITDA Margin	29.95%	26.00%	-4.76%
D&A For EBITDA	0.26	0.39	0.21
EBIT	1.6	1.17	-0.38
EBIT Margin	25.71%	19.49%	-10.73%
Effective Tax Rate	16.45%	18.11%	-
Revenue as Reported	6.22	6.02	3.53
Advertising Expenses	1	0.86	0.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q